甲状腺疾患の制御のための塞栓術による圧力対応逆行性閉塞療法（登録保護）：マルチセンター登録

Patients that may be included in the registry study are those who have undergone PED-TAE using TriNav at the selected study sites. Data will be collected on patients meeting eligibility criteria.

Study subjects will not be informed of their inclusion in this registry dataset, and the results of this research will not be reported to study subjects at the conclusion of the study.

Inclusion Criteria:

1. Adults, 18 years and or older and 89 years or younger

2. Having undergone PED-TAE using the TriNav Infusion System

3. Meeting one of the following criteria:

   1. Documented subclinical and or clinical hyperthyroidism in the presence of a toxic multinodular goiter or a toxic nodule > 20 ml
   2. Patients' ineligible or refusing surgery, radio-iodine therapy or percutaneous ablation
   3. Non-functioning multinodular goiters or nodule causing compressive symptoms including but not limited to neck pain, dysphagia, stridor, exercise induced dyspnea and/or pressure symptoms
   4. Bethesda category 2-3 (benign, or atypia or follicular lesion of undetermined significance) on 2 separate fine-needle aspiration biopsy (FNAB) results with a benign molecular profile with patient declining surgical resection

Exclusion Criteria:

1. Renal insufficiency
2. Unable to tolerate angiography including pregnancy and severe allergy to contrast media
3. Bethesda 4-6 on FNAB (suspicious for follicular neoplasm, suspicious for malignancy, or malignant)
4. <18 years old or >89 years old
5. Graves' disease or inflammatory thyroiditis (Hashimoto's) or other condition with the presence of an extensive collateral network as demonstrated or initial angiography
6. Presence of a bovine arch or any other anatomical variant with no inferior thyroid artery present
7. Prior thyroid thermal ablation